Marc Lajoie, Outpace Bio CEO

Out­pace Bio ex­pands cell ther­a­py R&D, nets re­search col­lab­o­ra­tions in Seat­tle

Out­pace Bio, a Seat­tle-based biotech that aims to cre­ate cell ther­a­pies, has ce­ment­ed its pres­ence in the Emer­ald City with a new fa­cil­i­ty and a pair of lo­cal re­search part­ner­ships with sci­en­tif­ic lead­ers.

The biotech an­nounced Tues­day that it se­cured a new fa­cil­i­ty in a 23,000-square-foot space in Seat­tle’s Dex­ter Yard to house the com­pa­ny’s R&D ef­forts. The com­pa­ny now has 53 em­ploy­ees and has grown from a plat­form com­pa­ny to a pipeline and plat­form com­pa­ny, both of which re­quire growth and more space, ac­cord­ing to Out­pace CEO Marc La­joie in an in­ter­view with End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.